Selected article for: "clinical development and critical need"
Author: Tavakol, Shima; Zahmatkeshan, Masoumeh; Mohammadinejad, Mohammad R.; Mehrzadi, Saeed; Joghataei, Mohammad T.; Alavijeh, Mo S.; Seifalian, Alexander
Title: The role of Nanotechnology in current COVID-19 outbreak
  • Cord-id: 8thmjvlt
  • Document date: 2021_4_15
    • ID: 8thmjvlt
    Snippet: COVID-19 has recently become one of the most challenging pandemics of the last century with deadly outcomes and a high rate of reproduction number. It emphasizes the critical need for the designing of efficient vaccines to prevent virus infection, early and fast diagnosis by the high sensitivity and selectivity diagnostic kits, and effective antiviral and protective therapeutics to decline and eliminate the viral load and side effects derived from tissue damages. Therefore, non-toxic antiviral n
    Document: COVID-19 has recently become one of the most challenging pandemics of the last century with deadly outcomes and a high rate of reproduction number. It emphasizes the critical need for the designing of efficient vaccines to prevent virus infection, early and fast diagnosis by the high sensitivity and selectivity diagnostic kits, and effective antiviral and protective therapeutics to decline and eliminate the viral load and side effects derived from tissue damages. Therefore, non-toxic antiviral nanoparticles (NPs) have been under development for clinical application to prevent and treat COVID-19. NPs showed great promise to provide nano vaccines against viral infections. Here, we discuss the potentials of NPs that may be applied as a drug itself or as a platform for the aim of drug and vaccine repurposing and development. Meanwhile, the advanced strategies based on NPs to detect viruses will be described with the goal of encouraging scientists to design effective and cost-benefit nanoplatforms for prevention, diagnosis, and treatment.

    Search related documents:
    Co phrase search for related documents
    • acid sensitive and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • activity remain and acute sars respiratory syndrome coronavirus: 1, 2
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and lopinavir ritonavir kaletra: 1, 2
    • acute sars respiratory syndrome coronavirus and lspr effect: 1
    • acute sars respiratory syndrome coronavirus and lymphocytic apoptosis: 1